Dr David Erritzoe

Summary

Podcast Summary: The Mid•Point with Gabby Logan

Episode: Dr. David Erritzoe
Date: February 4, 2026
Host: Gabby Logan
Guest: Dr. David Erritzoe (Clinical Reader in Psychopharmacology & Psychiatry, Imperial College London)

---

Episode Overview

This episode explores the renaissance of psychedelics as a powerful tool in mental health care. Gabby Logan welcomes Dr. David Erritzoe, an internationally recognized expert on the use of psychedelic compounds for treating mental health disorders such as depression and addiction. They examine both the misconceptions and scientific advancements in the field, discussing the therapeutic promise, clinical evidence, neurobiological mechanisms, and how psychedelics differ from traditional psychiatric medications.

---

Key Discussion Points & Insights

1. The Re-Emergence and History of Psychedelics

[01:36–05:56]

• Dr. Erritzoe shares his journey: from neuroscience and addiction research to investigating the effects of psychedelics like psilocybin and MDMA on the brain.
• He debunks common myths, such as psychedelic mushrooms causing trips that last days—most experiences last 4-5 hours (psilocybin) or a bit longer (LSD).
• The cultural history: Widespread therapeutic use in the 1950s–1960s (over 40,000 patients), followed by stigmatization due to the “war on drugs."
• Quote:
  Dr. Erritzoe [04:21]: “Apart from one myth we can shoot down, that mushroom experience lasts maybe four or five hours, not days... LSD a bit longer still. Not days.”

2. The Types of Psychedelics Studied

[06:12–07:39]

• Main research focus: Psilocybin (from mushrooms), typically in pure, synthetic or extracted form for accuracy and safety.
• Also studied: DMT (from ayahuasca) and 5-MeO-DMT (from toad toxin); clinical studies mainly use psilocybin.
• Additional work on LSD, MDMA, and ketamine, with ketamine already used in conventional medicine.

3. Clinical Trials & Results

[07:39–11:43]

• Early studies at Imperial College explored effects on “near-normal” healthy brains using brain imaging before moving into depression trials.
• Psilocybin shows particular promise for treatment-resistant depression (“patients who have tried a couple of conventional approved treatments, and if they still suffer”).
• Upcoming: Final phase depression trials for psilocybin may lead to FDA approval as early as 2027. MDMA for PTSD also in advanced stages but temporarily stalled.
• Quote:
  Dr. Erritzoe [10:24]: “Psilocybin is the most advanced one for mental health indications, and that is for depression, treatment-resistant depression.”

4. How Psychedelics Work—Therapy, Not Maintenance

[11:43–15:34]

• Paradigm shift: Not daily pills, but one or a handful of guided sessions embedded in a therapeutic process (“psychologically prepared... supported through it and then some psychological integration work”).
• Experiences vary: deep psyche material surfaces—trauma, beauty, spiritual revelations, often resulting in greater acceptance rather than avoidance.
• Integration work afterward is essential; therapy maximizes benefit and ensures safety.
• Quote:
  Dr. Erritzoe [14:19]: “Embedding in thoughtful therapeutic processes and efforts and support, we believe is the right way of using these drugs in a responsible way.”

5. Applications to Addiction and Mental Health

[15:34–18:02]

• Shared experience among mental health sufferers: trapped, disconnected, “stuck” feelings.
• Psychedelics can facilitate profound connectedness—to others, to inner emotional worlds, even nature, echoing themes in recovery programs (e.g., 12 steps).
• The risk of addiction to psychedelics themselves is extremely low due to their pharmacology (serotonin system—not the addictive dopamine system).

6. Clinical Realism—Not a Panacea

[19:44–21:59]

• Psychedelic therapy won’t be mainstream, first-line depression treatment. More akin to deep psychological work than standard antidepressant prescriptions.
• Model similar to deep psychotherapy or analysis, rather than brief, standardized treatments like CBT.

7. Brain Mechanisms and Analogies

[22:04–25:38]

• Analogy: The brain as a snow globe or mountainous landscape—psychedelics “shake up” entrenched neural pathways, increasing malleability and plasticity.
• After the experience, brain “landscape” is flatter, allowing new routes and behaviors, supporting lasting psychological change.
• Animal data suggest new synaptic growth; human research ongoing.

8. Challenges and Future Potential

[25:38–32:53]

• Speculative potential for neurodegenerative conditions (e.g., Alzheimer’s)—but risks due to psychological intensity; most focus remains on mental health disorders.
• Global landscape: UK leads in science; Switzerland, Canada, Australia, Jamaica, Costa Rica, and some US states are pioneers in clinical/compassionate use.
• Real-world data (“phase 4”) being collected internationally will inform policy and safety.

9. The Ketamine Bridge

[32:53–39:31]

• While classic psychedelics aren’t yet legally available for therapy in the UK, ketamine (anesthetic with rapid antidepressant action) is.
• Gabby raises concerns about recreational ketamine abuse and dependency. Dr. Erritzoe clarifies distinctions: recreational use is contextless, but structured clinical use with therapy rarely leads to addiction.
• Quote:
  Dr. Erritzoe [36:37]: “These drugs, if they're used out of hand, out of context and too high doses too frequently, people can be dependent outside of clinical care… But if you use them in a therapeutic frame, it's saved.”

10. Who Benefits? Are Psychedelics for All?

[40:10–41:59]

• Not everyone will benefit—no universal magic bullet. Careful selection and monitoring are crucial; some could experience psychological challenges.
• Microdosing (very small, frequent doses): Placebo-controlled studies often show benefits are mostly from expectation effects rather than pharmacological action.
• Quote:
  Dr. Erritzoe [41:41]: “You will get amazing improvements in all studies [of microdosing]. However...the data from...the placebo suffocates the effects seen in the other arm.”

11. Risks and Contraindications

[43:52–46:13]

• Psychedelics avoided in those with a history of psychosis, unstable sense of self, or particular personality disorders—could destabilize vulnerable individuals.
• Autism and emotionally unstable personalities: possibly helpful for some, but higher risk of difficulties; always require expert monitoring.

12. Stigma Reduction, Policy, and Hope

[46:13–49:18]

• Science and media coverage are helping destigmatize psychedelics.
• “Interventional” psychiatry (short, intensive treatments—like physiotherapy) vs. maintenance medication is appealing for many.
• Quote:
  Dr. Erritzoe [49:18]: “You can get better. It’s an effort but...it’s an intense period. It’s not that you’re parked on a drug.”

13. Addiction Recovery: Outcomes and Timeframes

[47:42–48:59]

• Profound “mystical” experiences during psychedelic therapy often correlate with better clinical outcomes in addiction.
• Effects may be immediate (like ketamine in depression); work after session is crucial for maintaining gains.

---

Notable Quotes & Memorable Moments

• On safety and support:
  Dr. Erritzoe [14:19]: “Embedding in thoughtful therapeutic processes and efforts and support, we believe is the right way of using these drugs in a responsible way.”
• On addiction risk:
  Dr. Erritzoe [18:02]: “These drugs are very, very different. And they do not form addiction...they don’t get people dependent. It’s not that you seek a rush after.”
• On the brain:
  Dr. Erritzoe [23:35]: “What happens in the psychedelic state acutely, is that all that is shaken a little bit like a snow globe...the brain becomes very flexible and moldable.”
• On scope for societal benefit:
  Dr. Erritzoe [29:02]: “What you get...there are so many things that the psychedelics also typically in our studies and other people's studies bring with them that it's kind of a bonus in a world that is going down in climate problems, having people more connected to nature.”
• On global leadership:
  Dr. Erritzoe [30:54]: “Healthcare wise, it’s Canada, Australia and Switzerland and now also Czech Republic and Germany more recently that are changing and several states in the US So it’s more and more.”

---

Timestamps for Important Segments

• Introduction & Dr. Erritzoe’s Background: 00:39–03:59
• History of Psychedelics & Myths: 03:59–06:12
• Types of Psychedelics Studied: 06:12–07:39
• Clinical Trials & Results: 07:39–11:43
• Mechanism & Therapy Model: 11:43–15:34
• Addiction, Connectedness, and Risk: 15:34–18:02
• Access, Ketamine, and NHS Potential: 32:53–39:31
• Brain Mechanisms Explained: 22:04–25:38
• Contraindications: 43:52–46:13
• Societal Attitudes & Stigma: 46:13–49:18
• Addiction Recovery & Outcomes: 47:42–48:59

---

Final Thoughts

Dr. Erritzoe offers a balanced expert’s view: psychedelics are not a miracle cure for everyone, but data show their potential to revolutionize the treatment of depression, addiction, and potentially other mental health disorders. Proper support, careful patient selection, and further research will be critical as this powerful therapeutic paradigm enters the mainstream.

---

Structured and summarized by The Mid•Point Podcast Summarizer. For more detailed references, listen to the full episode or consult the latest peer-reviewed findings by Dr. David Erritzoe and colleagues.

Transcript

[Land Rover Narrator]

It's time to set your sights on higher peaks to scale, deeper rivers to cross and greater dreams to pursue. It's time to embrace the impossible with Defender. Built with legendary capability and tested on some of the most difficult terrain, Defender defines tough luxury. From the sleek two door Defender 90 to the purposeful Defender 110 to the Defender 130 with seating for up to eight, there's endless potential ahead.

[Podcast Host]

Expectations.

[Land Rover Narrator]

Explore the full Defender lineup@land roverusa.com.

[Podcast Host]

Hello and welcome to the Midpoint. We've got something a little bit different today. I've been fascinated by the increase in the noise around the use of psychedelics for mental health issues for a while now. While not knowing anything about it, it really is outside of my comfort zone. But late last year I was made aware of Dr. David Arettzo and the work he's doing in this space. And he's a clinical reader in psychopharmacology and psychiatry at Imperial College London and the cnwl Mental Health NHS Foundation Trust. And since David arrived at Imperial in 2009, he's conducted and overseen clinical and neuroimaging trials into the treatment of disorders and addictions using psychedelics and has authored 145 peer reviewed scientific papers and five book chapters. So I feel we have the right person here to tell us all we need to know about this growing area of medicine. So let's go meet David. Dr. David Arizo, welcome to the Midpoint.

[Dr. David Aborizo]

Thank you so much.

[Podcast Host]

You've just revealed as you walked in that you've come fresh from Davos, which I think actually tells us, and I said in the introduction, the increasing noise around psychedelics, I think that tells us everything we need to know about the direction of travel of psychedelics in the mainstream. If you're, if you're invited to talk

[Dr. David Aborizo]

at Davos, then at least just in a psych program, but still quite a lot of, of airtime down there for

[Podcast Host]

what we're doing because the money men must see there's an opportunity here, right?

[Dr. David Aborizo]

Yeah, I think so.

[Podcast Host]

So I also, in your introduction say I know nothing about psychedelics, I've never done them, but I also am probably one of those people that needs a few myths busting about them. So I hear the noise and I hear the, the good work that potentially is being done in terms of mental health issues and addictions, but understand how they work. So we've got a lot to get into.

[Dr. David Aborizo]

Yeah, sounds good.

[Podcast Host]

Tell us how you started in this area and what drew you in.

[Dr. David Aborizo]

So I came from medicine and neuroscience and during my PhD 20 years ago. I came in a bit of a boring, nerdy way, because the place I was trained, they were very good at methods to understand the brain serotonin system in particular. And, and I got interested in the biology behind addiction because there's a lot you can actually understand from the brain about addiction then. The methods we had available were actually on the side of that. And therefore, when it came to drugs to understand impacts on the brain in that system, the drugs that are very active there and work in that system are psychedelics and mdma. And therefore I ended up pursuing, trying to understand the effects of those drugs. In the beginning it was about the impacts of, you know, recreational use of the drugs. And then when I moved after my PhD here to London to Imperial College, the colleagues there were planning work to try to understand the drug when we gave the drug, instead of just trying to understand the impacts of people using them, then try to see what they do to the brain. And looking back in history and the knowledge already existing, a lot of wisdom there around these compounds, how they can be beneficial. So then it sort of took that, that direction. Not just us, also Johns Hopkins and a few other places were pursuing that. So it was an early opening of this new era of interest in psychedelics.

[Podcast Host]

So when you mention the recreational use, we think back to kind of the 1970s, in particular, late 60s 70s and the association with the hippie movement and people going on trips that could last days, usually using mushrooms or kind of things like that. So is that what you're talking about when you say recreational use?

[Dr. David Aborizo]

Yeah, I mean, apart from one myth we can shoot down, that mushroom experience lasts maybe four or five hours, not days. LSD a bit longer still. Not days, unless you keep on taking it. And if you do, they actually don't work. You very quickly get tolerant. So it doesn't really work if you take them days in a row. So it's not days that people were tripping on these drugs. But yeah, there was a big sort of counterculture in the Western world using these drugs and having great communities and experiences and use them for some of the things that are actually therapeutically relevant, also for the development we're in now. And there were also, in that era, in the 50s and 60s, 40,000 people, patients or so, being treated by clinicians with these treatments. And then war on drugs, late 60s, around 1970, new UN conventions, Nixon war on Drug, counterculture. Also impacting into perception around Vietnam War. So there are a lot of reasons why they were pretty demonized and a lot of myths were also in the interest of some people to create and therefore got pretty bad names, which also in a way informed somewhat why we focused on the mushroom compound called psilocybin instead of LSD. Because everybody knows, let's say 20 years ago, super stigmatized LSD where psilocybin nobody could spell or pronounce. So that was psilocybin.

[Podcast Host]

Psilocybin, okay. And that's the mushroom compound. So are the psychedelics that you're dealing with and the research you are looking into and have done and all the papers just dealing pretty much with mushrooms, Is that what you're focused on?

[Dr. David Aborizo]

Most of what we have been doing in our team is on psilocybin. Absolutely. So it's not actually necessarily coming from the mushrooms.

[Podcast Host]

Right. So it's synthetic.

[Dr. David Aborizo]

Yeah, you can synthesize it. Some of the new trials we are doing, it actually has been extracted and purified. So it actually comes from mushroom. But we're not giving the mushrooms. It's difficult in drug development because of all the other things in the mushrooms. It needs to be quite pure for us to be sure that we know what we are testing exactly and get it through these processes and approval processes. So we work with the pure compounds, but we also do work with dmt, which is another classic psychedelic related to psilocybin. That's the one that people might have heard about, or maybe not heard about that name, but it's the psychedelic active compound in the Amazonian brew called ayahuasca that has thousands of years of cultural ceremonial, shamanistic use. So the psychedelic from there that also comes from nature like psilocybin as DMT and then a third one, 5 Meo DMT comes from the toxin in a toad. And that one we have also done a bit of work with, but for the sort of clinical studies and people suffering mental health conditions, most of what we have been doing is with psilocybin. We've also done work with LSD and MDMA and ketamine, but mainly psilocybin.

[Podcast Host]

So in terms of the mental health issues that you're looking at and addictions, what are you coming to the kind of conclusion of in all the work that you've done in terms of how effective they can be? And is there a specific area of mental health where you're getting better results than others?

[Dr. David Aborizo]

So, you know, bringing this field back, us and others, not that many actually, 20 years ago, you know, we needed to make some decisions what compound to focus, also how to give it. Should we give it intravenously or through the mouth with psilocybin, or should it be lsd? And what indication, once we had done the initial work, got familiar with the experience that people are having and the effects and the safety and the dosing and also some of the imaging work that we did in people without any mental health indication to understand the drugs and how they work and what is the brain signature of these experiences that had never been done before because in the first era we didn't have the scanners. When I say we.

[Podcast Host]

So you would look first of all at somebody who had a healthy brain and good mental health.

[Dr. David Aborizo]

I heard it actually in Davos. A colleague said near normal, which might be a nice term.

[Podcast Host]

Near normal brain.

[Dr. David Aborizo]

Yeah.

[Podcast Host]

So you would be able to see the effects of the drugs on the brain, literally through scanning.

[Dr. David Aborizo]

Yeah, exactly. And some of what we saw there added to the list of good reasons to consider taking it in the direction of depression. And so that is what we decided to do. So we did the first study in modern time with any psychedelic for a group of people with depression and saw really good results. That was not a perfectly designed trial. It was proof of concept. You can make trials more complex and sophisticated and this one was an early proof of concept to see if we could do this safely and what came out of it. And also with brain imaging again. And we did that. And in a way then that was taken forward by others and there were new companies forming in the space and they have then accelerated that development, taken that further and done the next lines of, of next line of trials. And now it's in the late, the final phase of testing in patients. So that means the psilocybin is the most advanced one for mental health indications and that is for depression treatment, resistant depression. Meaning nothing else has worked? Yeah, I mean, not nothing else, but they have tried a couple of conventional approved treatments, insufficient dose and duration and so on. And if they still suffer with the depression, which we already know that there's quite a large group doing, then they can enter that trial and that trial is completing and in follow up. And that's not us doing it, but that came from the early work. The early work.

[Podcast Host]

So when you say completing, I know it takes a long time, doesn't it, to get a medicine on the shelves and for a doctor to be able to prescribe it. How far away is that trial from that stage?

[Dr. David Aborizo]

I think already in a year it might be filed around that time to the fda. The focus always typically is on America due to the market and then other markets and Regulatory bodies to send in the data for considering approval will happen in the UK and Europe after that. And then they take a while to consider the data and so on. So it could happen during 27 with psilocybin, MDMA, which is not a classic psychedelic, some more atypical psychedelic, but very, very fascinating. Interesting compound. We have not done that much work with it, but just to put that in there, that the trials were completed, it was filed and now it has been rejected initially and more work needs to be done with MDMA so that several of them might end up coming quite close to each other. And that's for PTSD with mdma.

[Podcast Host]

Right?

[Dr. David Aborizo]

Okay, yeah.

[Podcast Host]

So can you explain how it's actually working and in terms of how it's. Is it rewiring neural pathways, is it changing the structure of the brain forever? Or is this something that somebody's got to be on for, you know, for the rest of their life?

[Dr. David Aborizo]

Yeah, so I think an important detail for people who are not that familiar with these drugs, the model, the paradigm is really different from giving a person a tablet, conventional antidepressant medication, SSRIs that is used for a lot of indications. People take them daily for a long time. Psilocybin and the other classic psychedelics, they are framed and packaged into a therapeutic context and given very, very few times. So it's a single standing session or a few where you are under the influence of this drug after having been psychologically prepared by the team and then supported, guided, supported through it and then some psychological integration work.

[Podcast Host]

So what's happening in that period of time then when you've taken the drug?

[Dr. David Aborizo]

So in the session where you actually take the drug, then you feel the experience of the drug and it's not very easy to predict what comes up because they are sort of access into your deep psyche in a way. That's also what the word psychedelic mean. Mind or soul revealing or manifesting. So things come up deep. Psychological material can be interrelational, it can be trauma, it can be beauty. It can also be more spiritual bliss type revelations. Reframing often as profound, but really has been a theme when we do interviews and get people's stories, people's narratives for what happened and what was helpful for them. A theme is that people often out of these sessions change from a degree of avoidance, which is a big thing in any mental health condition, which also speaks to why they might work across that things are so difficult that you can't really approach and work with it and face it. And some of that Often on a psychedelic afterwards goes in the direction of some degree of acceptance and coming to terms and it settles.

[Podcast Host]

And that's a permanent state. Then

[Dr. David Aborizo]

in these trials, let's not make them absolutely too amazing and magic bullets.

[Podcast Host]

That's what I mean. Is it something that you've still got to that person has then still got to have therapy to work through that?

[Dr. David Aborizo]

That's the way we use them. That's the way the paradigm has been and also back in the days used when it was used thoughtfully, safely. But it doesn't mean that people who have a psychedelic experience can't really get a lot out of it without any psychological package. They often can. But then the risk is also that it can be overwhelming, challenging psychologically and difficult and maybe end up be disturbing for the person. So therefore, that whole embedding in thoughtful therapeutic processes and efforts and support, we believe is the right way of using these drugs in a responsible way. And that's why we do it like that. And also, if you have all these insights and opportunities for some positive, meaningful change, whether it's lifestyle, psychological reframing, so deep psychological processes that in order to really get max out of them and use them fruitfully and also work safely, thoughtfully with therapists to support you, then that work after integrating it and finding out how to integrate it into your life to move in a better direction, to break habits.

[Podcast Host]

And that's where addictions can come into play as well.

[Dr. David Aborizo]

Yeah, absolutely. And because a lot of mental health, whether it is depression, anxiety, also ptsd, even eating disorder, OCD and those are all. And then addictions, all conditions that we are investigating with these compounds, and there are some shared features in these where I think psychedelics are incredibly interesting and powerful. So this feeling of being trapped, this feeling of being stuck is very classic. No matter who you speak to, who really suffer from a mental health condition, no matter which one of them in different ways, and also a very sort of negative bias and a bit inverted into your own life and lack the connection to others and what happens around you and being part of something bigger, a bit like 12 step kind of thinking some higher power or being more connected and psychedelic is one of the absolute key features that people very often express very clearly is a profound sense of being connected, can be to others, can be to your own more emotional life, the difficulties and the beauties, but also even nature, even the universe, and also this transcendence that we are part of something that goes forth and back through time and space. And that sounds very spiritual, but that is really very Classic with these.

[Podcast Host]

And as you point out, that's kind of the. The thinking on the 12 steps, isn't it? In terms of being part of something greater than yourself.

[Dr. David Aborizo]

Yeah.

[Podcast Host]

Which.

[Dr. David Aborizo]

And interestingly, sorry. Wilson, one of the founders of of AA program, the 12 step, he recovered himself after having tried, I think, a number of times. Then he had an altered state of experience with a compound. Not any of these ones, but. And. And that really, really helped him and that made him recover and maintain abstinence. And there were discussions between him and others early on about integrating psychedelics into the 12 step program, because it actually fits really well, but that was not that well received.

[Podcast Host]

Seem much more difficult to grow 12 steps as they did. Wouldn't it at the time if they'd

[Dr. David Aborizo]

had to in a very stigmatized group?

[Podcast Host]

Yeah, yeah. And so immediately my kind of thought is, well, if you've got somebody who has got some addictions, why would they not become addicted to the feeling they're getting when they take the compound?

[Dr. David Aborizo]

Yeah, that's a meaningful and also very logical question. I mean, it's because they are not euphoric, pleasant, easy experiences. And also due to some of the pharmacology, these drugs work very specifically in the serotonin system of the brain. The drugs that people get addicted to typically work in the dopamine system, opiate system of the brain. All the others you can think of that, you know, that people can get in trouble with. Yeah. So these drugs are very, very different. And they do not form addiction. They do not push people out to addiction. Mdma, tiny bit more, but it's also a little bit different pharmacology. And then you have ketamine, that's also a related compound, but have more likelihood, different pharmacology, with some downstream effects on the brain that are overlapping with the classic psychedelics, but that also has more risk of people becoming addicted. Still a very interesting, also therapeutically very interesting compound. But the classic psychedelics do not really. They don't get people dependent. It's not that you seek a rush after. It's not that it hijacks your brain's reward circuit like some of the others do. Often, actually, people say that they don't need an experienced extra. That was tested early on, that was for smoking cessation by our colleagues at Johns Hopkins. And they offered, I think, people a third experience with psilocybin. And most people said they didn't really want that. It's challenging, it's an effort. It's a lot of work. It's a Lot of things that are brought to surface that you need to deal with and work with. And again, why we want to embed them in therapy.

[Podcast Host]

So from what you said there and before then, the people who are most likely to get a successful outcome will be very invested in their. This is not something that necessarily is just going to be dished out by a GP at the first meeting of somebody having depression.

[Dr. David Aborizo]

No, not at all. And actually they're not likely to come. They're not going to come as first line treatment. Like very few things like in sort of it it will be.

[Podcast Host]

But you know, when you hear people kind of very glibly saying, well, they should be on antidepressants, they need to be on antidepressants. And, and apparently, you know, from people that I've spoken to, they're not that hard to come by. Antidepressants. No increasing number of people in the world, in the western world on antidepressants. But this is not that.

[Dr. David Aborizo]

No, it's not going to rip. It's. It's. Okay, let's. As a sort of parallel, if you think about cognitive behavioral therapy, it's a relatively regimented, maybe 10, 12 sessions, kind of very manualized with some homework. And so if we compare normal antidepressants like SSRIs to the. Then the psychedelics are more like deep analysis work. And if you look at who's getting what kind of talking therapy, most people are getting some CBT1. So this is deeper, more complex, more invested work and it will be done by people who are trained in it and not prescribed to use at home. And that's the model. Of course, it's in the interest financially and due to regulatory constraints as well for some of the companies developing these new treatments to get rid a bit of the talking therapy. And that's a big issue because that is not the optimal and best way and also most effectful way and most safe way of using them without if you take all the psychology, the therapy away. But that's where the model, this paradigm struggled to fit perfectly into the existing structures, existing structures for how to get a new treatment, a new drug to market. This is a mix of talking therapy and pharmacology. And that is confusing for the system. It's not really the system's fault. They just regulate it and consider drugs and not talking therapy. And this is a mixed model.

[Podcast Host]

Is it possible to describe what the brain looks like when somebody is having a psychedelic experience?

[Dr. David Aborizo]

Yeah. So normally through development from childhood and to adulthood, your brain through experience becomes more and more efficient, more and more connected. Different parts of the brain need to be efficiently connected and work together in order to efficiently and quickly, with minimal effort, solve tasks and understand and process input and so on. And if that is done in a sort of unfortunate way, maladaptive way through life experiences and you end up suffering with a mental health indication conditions, then some of these pathways are maybe not optimal. What happens in the psychedelic state acutely, is that all that is shaken a little bit like a snow globe, if you imagine one of those, because it's a closed system. It's not that anything adds to the brain, it's still the brain. But if you shake that and the snow falls, it might be that the little snowman or Santa Claus in the snow dome has a path through the snow in a specific direction to get from A to B, from his little house over to, I don't know, the workshop making the Christmas present or whatever. And once it's really being shaken in the experience, and then the snow gets up and falls down, and then he can in a way take many different paths. So it allows for a bit of a reshape, remolding. The brain becomes very flexible and moldable.

[Podcast Host]

And in a scan you can see,

[Dr. David Aborizo]

yeah, we can see the brain meshes of these phenomena. We can even see to continue with snow and our brain into mountains. So, yeah, so if we, instead of being in the snow, that we are in a big area with mountains. Yeah. Then there might be a path to ski down that you have used many times for, and that's easiest to use. But after, with the shake of the mountain, you can go different directions. But to make it even more fascinating, and this is maybe take the analogy far, but it, it's something we have brain data on that let's say you want to go from this area of this mountain chain to another one, to another place. If the mountains are very tall and the valleys are very deep, then you will have to take the easiest route. And that will be the same route every time. And you're a bit constrained in how you can move across. It's complicated to get from A to B. But with the psychedelics also after the experience, we can see that in a way the landscape is flattened, there's change to the hierarchy and there's a flattening to the landscape of the brain activity. And that means that there's an opportunity to consider different paths. And all that comes on a foundation of brain plasticity. So a window or opportunity for the brain to reshape and reform. And even Sprout will some new synapses, some new connections. Most of that we know from animal work. With psychedelics, we are heavily investigating as well as we can with the methods we have available in humans at the moment. But they are very powerful in inducing a very plastic, biological, plastic brain. And if you then have these profound experiences in such a plastic state and an ability to reshape a bit and take new paths, that is in a way, how the psych hearing, you describe

[Podcast Host]

that and that great analogy. I'm thinking about people who might have Alzheimer's, earlier onset of dementia, those. Those kinds of mental illnesses and diseases. Would there be any impact at all that psychedelics might have on those kinds of brains?

[Dr. David Aborizo]

Yeah, I know it's not your area

[Podcast Host]

of expertise, but you've heard any work.

[Dr. David Aborizo]

Yeah, it is. It is something that people are starting looking into. It's more in the sort of neurology side of things. The issue is that these experiences that can be very profound, very deep and also a little bit unbelievable what comes up psychologically, your perceptions, your visuals, all that is changing during these experiences, giving that to a person who struggled to provide the consent. It's a bit of a possibly brutal thing to a person who is quite unwell with dementia, but very early stage. Could you, or those who are genetically

[Podcast Host]

predisposed that we now know obviously have a genetic link, Would there be potential?

[Dr. David Aborizo]

Possibly. And it could also be that you could do some tasking in order to sort of train the brain and you might do that on some low doses of psychedelics to have that plasticity. The opportunity for the brain to improve could potentially be improved by psychedelics, but there's not much yet in that direction. It's so far has mainly been in the mental health side that we have investigated. The field has been moving also because there's a. Yeah, also there. Same for Alzheimer, but there is a lot coming for Alzheimer. There's been a lot of resource put in mental health absolutely under prioritized for many, many, many decades, completely out of proportion to other fields of medicine. And there's a massive underserved group of the population of patients with a lot of diseases not even having any medication. That's also why we, for instance, are launching new trials in gambling disorder with psychedelics and also opioid use disorder, because of all the incredible horrible mortality, mortality.

[Podcast Host]

And for government, it has to also be an incentive to save money, doesn't it? So can you see a world in which the NHS is actually prescribing psychedelics? And it's obviously Saving money down the track. Because that's what drug use ultimately comes down to, isn't it? It's a financial consideration for the government.

[Dr. David Aborizo]

Absolutely. And in a way, fair enough. When you have X amount of money and you need to prioritize it, you need to do the health economics. But the suffering, and I mean the mental health indicates. But depression, the most prominent one in terms of burden of disease and also how much it costs society. There's.

[Land Rover Narrator]

It's time to set your sights on higher peaks to scale, deeper rivers to cross and greater dreams to pursue. It's time to embrace the impossible. With Defender built with legendary capability and tested on some of the most difficult terrain, Defender defines tough luxury. From the sleek two door Defender 90 to the purposeful Defender 110 to the Defender 130 with seating for up to eight. There's endless potential ahead. Explore the full Defender lineup@land roverusa.com

[Dr. David Aborizo]

Really a lot to gain. So I would put it the other way around. Say can we afford not to help people if we have something new, a new paradigm that actually does look really, really promising. You also asked earlier that I didn't really address how they work, how efficient are they compared to what we have? And it looks like a bit more efficient in terms of the health data for the different indications or typically more efficient than what we have right now. That's how it looks and that's why it's very exciting at the same time being a complicated new paradigm. But if you think about what you get. So if you just see the hard meshes of let's say depression, that's one thing. Think about all the addition things we have already talked about. Increased related connection to nature, increased connectedness in general, pro social traits being pushed and enhanced agreeableness trait going up, openness, flexible psychological thinking, creativity and so on. There are so many things that the psychedelics also typically in our studies and other people's studies bring with them that it's kind of a bonus in a world that is going down in climate problems, having people more connected to nature. There's a lot of extra things that we do not regulators do not look at when they just need to look at the hard measures and do the health economics. But I would say we need to be able to fund such treatment paradigms to be implemented into healthcare, including nhs. And we are piloting stuff into NHS at the moment.

[Podcast Host]

Who's doing it best globally then you're from Denmark originally, you study here or you've done a majority of your study here and Your papers. Is there any other, are there other countries who are really leading the way in terms of integrating psychedelics?

[Dr. David Aborizo]

Yeah, there are, I would say the uk strong in the science development and the understanding of these drugs in early trials. In the beginning, imperial, but also now other great colleagues at other institutions in the uk, America, always in there. But what has happened is that some countries have in a way stepped forward clinically by allowing early access, compassionate use clinically. And that those countries are Switzerland early on 2014 and then Australia, Canada. There are places where there are sort of gaps and gray zones where people can use and provide these drugs. So I think Jamaica, Costa Rica, there are a lot of people there offering. There's a gap in the law in Holland allowing psychedelic truffles to be used. But healthcare wise, it's Canada, Australia and Switzerland and now also Czech Republic and Germany more recently that are changing and several states in the US So it's more and more.

[Podcast Host]

You're learning a lot from those, those countries as well.

[Dr. David Aborizo]

I mean, in a way, yeah, we can, if data is collected, if they have good employees that are being used, national registries collecting data from real world use, clinical use that then that is really important. That's something called phase four. So after the 1, 2, 3 clinical phases of testing on new compound, then it's out in reality that in real world that's actually what they kind of are doing before the phase three trials have been completed. Yeah, even completed. And that I think is meaningful. I think it's okay as long as you do it in a thoughtful way and you monitor it and you use the understanding from what is used.

[Podcast Host]

So if somebody's listening to this now and they're feeling quite desperate for themselves or somebody they love and they think this could be the way that they could help them or themselves, is it possible in this country to go and safely use psychedelics?

[Dr. David Aborizo]

Yeah, it is. But because humans have used these drugs, and I'm not going to say just because we sit and do that, people make it because they grow out in nature, you know, the psilocybin, but doing it in a, you know, meaningful setup with clinicians and therapy that you can't do in the UK because they don't have that, not decided to do what some of the other countries do with early access programs used clinically. However, and this is actually my main thing, and that is what we are piloting at the moment, there is a bit of a forgotten perfect solution to bridge the gap, to serve the demand of patients asking for these treatments because they have Read about them and heard about them. And that's ketamine. Ketamine is already a medicine. It has started as a medicine. It just used in physical health, in intensive care, for other indications. Also a sedative in higher doses. If you use it in a lower dose, it's antidepressant. And actually also trials that show it work for other indications, such as alcohol use disorder. That is work done in the UK by Exeter Celia Morgan.

[Podcast Host]

There are stories, though, about ketamine in the news are about ketamine addiction and ketamine being something that's being used as a recreational drug.

[Dr. David Aborizo]

So, yeah, so it's a complex story still. It's a complex story, but that one does not rule out the other. If we were to, for the first time, introduce some kind of opiate treatment that's still incredibly useful if you've broken your leg and you're in hospital, doesn't mean that it's absolutely great idea to use wildly every weekend. You'll be dependent.

[Podcast Host]

But is it the same? So somebody this weekend who is using ketamine in a recreational manner, is that the same thing that you're talking about using? Is it the same compound or is it.

[Dr. David Aborizo]

It is. So a company did something to the compound chemically and then did all the trials, put billions into it and developed it and had it approved also in the uk, as a nasal spray formulation. That one has a license, it's expensive, not endorsed by NICE guidelines to use in the nhs, really. So therefore it's not really available, but it has a license, it can be used, but the old version of it, which is kind of the same as people are taking the streets and the same as my clinical physical health colleagues use in all hospitals, all over. And also if you drive a doctor out to a traffic accident, ketamine is used there, but in the lower dose, same drug cost, nothing that should be. And that is what we are piloting in a talking therapy model into nhs. My big encouragement is to put pressure on to do more of that because it will take a while before the others are there. Not only will it give access for a very related model of treatment that is fully evidence based, there's tons of evidence for that ketamine, a series of dosing sessions work and that it can be safely and meaningfully embedded in therapy, similar to what we do with psilocybin and mdma, it would also serve an incredibly important purpose in addition to give access for patients, and that is to prepare the system to find out how do we smartly without inventing and putting really clunky, expensive, complete new treatment services into the nhs. How can we navigate what's already there? What training experience, what staffing, what care paths are there? And that's what we are trying to do.

[Podcast Host]

What I'm struggling to understand there is how it has become such apparently an insidious drug for young people hearing stories of, you know, bladder failure and people, you know, becoming seriously addicted to the same compound. Is it just dosage? Is it.

[Dr. David Aborizo]

It is that when. So if you use these drugs to.

[Podcast Host]

And why are those. Sorry to interrupt, but why are those kids who are using it not having the psychedelic experience that you're talking about?

[Dr. David Aborizo]

Yeah, I understand that it is confusing when the drugs are used, they're very, very context dependent. That's one thing. If the model, the clinical model you're setting up has X number of treatments, let's say five sessions, that's what we are currently piloting, one every week embedded in 10 sessions of therapy. And it's done. Joined between the talking therapy services in the NHS and us on the psychiatry side, we work together, joint supervision and so on. We're all co thinking about and with this patient that we are trying to help, we implement behavioral activation with goal setting and so on into the model. Then it's a very contained, supported model and people that are being offered the treatment like that in a clinical setting, they are motivated, they are working, taking agency and involved in their own recovery. In such a model, they don't go out and do it completely out of context, they're. They don't go out on recreationally dose the drug to have a fun time. It's a completely different use of the drug and people do not seem to seek it. So you wouldn't. I can't rule out that if you treat 1 million, there will be a few who will end up buying it in the street and be heavily dependent. But that might be the case. But we already know you wouldn't treat

[Podcast Host]

a ketamine addict with ketamine.

[Dr. David Aborizo]

We could. You could, yeah. Potentially. I don't think it has been done, but possibly, yeah. And I know it's confusing. I would say that also you can say if you are 17 year old and you eat mushrooms with your friends and you run down the mall and have a funny, giggly time, is that therapeutic? Not probably not that much. They are very, very contest. And when people say, but if you close your eyes and go inwards and use it in an, in a setting, in a surrounding, with the music, the blindfold, the therapeutic support the preparation to go into it, then you are using that drug in a very, very different way from if you go to a rave and take it. There's nothing wrong. I mean you can say that's a, that's a political policy, legal thing. Whether you think that's wrong and that's drug policy and we can discuss that. But it, that's not obviously the core of my expertise and field of work. But you. Yeah, these drugs, if they're used out of hand, out of context and too high doses too frequently, people can be dependent outside of clinical care with the same compound again a bit. Think about the opioids. If you have broken a leg or you undergo surgery, it's not that everybody then run out and become addicted to heroin after having been given when they need it in a specific. And this is even framed more safely because it's saved in a therapeutic frame.

[Podcast Host]

Right. Okay. So we've got to kind of think of it in that way, in a

[Dr. David Aborizo]

medicalized way, almost catalyzed psychotherapy. Right. More than a medical. Yeah, it's medical, but it's way beyond just the biological agent to the brain. We use it for psychological work to catalyze that work. That I think is the best use of these compounds. They might, some of them come out in a very biological model, the nasal spray, very biological. But if you really want to use all the beauty of what these drugs can do to your mind with your mind for yourself for reframing, they are best used together with talking therapy in

[Podcast Host]

terms of a near normal brain that we called it earlier on, what would the benefits, if any, be? Would it ever come to a state where you'd say, because you hear the expert, everybody can benefit from therapy. Even an person could benefit from that. Would everybody benefit from psychedelics?

[Dr. David Aborizo]

That I would categorically say no, not everybody would because there is no such thing. That's I think magical thinking that anybody. But overall, we already know from studies in healthies, many centers have done it, we have done it that people overall benefit. There might be a couple who struggle. It might open up something that requires some psychological work after. Definitely. But overall, when we look at the data, we also have population data where we do surveys onto real world without any clinical input, where we don't even meet the people. Or sometimes we do trials where we give neonormals like this and do people. When we measure measures of psychological well being and different other interesting features in a near normal person, we do see improvements overall. So if there are some people where it's tricky Then they sort of drown in the data because most people really benefit. And then the million dollar question is, is that something we should also then develop the drugs for? Right? Yeah, but is that not.

[Podcast Host]

I mean you hear about microdosing and people doing their own kind of and you're smiling away there.

[Dr. David Aborizo]

What I've just been endeavors to having

[Podcast Host]

that there's a lot of microdosing going on there.

[Dr. David Aborizo]

No, but there's some prominent wonderful colleagues working also in microdosing. One of those Paul Stamets from North America. And we have different views on the data and the evidence for microdosing. So yes, a lot of people are microdosing. What is it doing a big industry around it as well.

[Podcast Host]

Is it purely for recreational use or does it have any impact on their day to day cognitive function?

[Dr. David Aborizo]

My take on it right now is that if you do a study really testing microdosing, you will get amazing improvements in all studies. However, when you bother to randomize people, meaning you allocate them to either the microdosing or to an inactive placebo condition, you test them and you make sure people don't know what they got. Then the data coming from the arm of the study that had the placebo typically suffocates the effects seen in the other arm. And that is, that is what you need to do scientifically to actually understand whether it's a real effect or whether it could be driven by expectancy and placebo effects. And for microdosing specifically, which is not the same as what we just talked about with full doses with an altered state of consciousness in a safe setting, the microdosing is regular use several times a week for a longer period of tiny doses of the same drugs. They might give a little bit of plasticity and they could maybe be tested together with other inputs. Could be meditation talking therapy, lifestyle changes and so on. Those studies need to be done on its own. Does it work if you ignore the placebo arm and that regulators don't, medics don't, investors don't. So that means if you are individual and it helps you, even if it was all placebo, who cares? But it does for drug development and to get them into medicine. So I would. And it has been tested for a few mental health indications. There's an ADSD study with LSD microdosing, great improvements, but exactly the same in the placebo group. Right. So microdosing is maybe not the hottest topic for psychedelics in terms of drug development and investments, but it's a big market outside of medicine. That's what makes psychedelics confusing?

[Podcast Host]

Because I've got to ask you about the downside and the contraindicators that you've experienced or you've seen experienced, what would they be?

[Dr. David Aborizo]

So so far we have cautiously, when we try to take understand the people going into the trials, we take mental health and physical health history, family history and so on. So people who have experienced psychosis, we have not included in trial for caution. There's some data from the 50s, 60s that that could be very problematic to do. If part of what you are struggling with involves some degree of fragmentation to your sense of self, to your ego, understanding and boundaries around the ego, then it might be destabilizing to in a way make that more fragmented in the state of a psychedelic, at least theoretically and with some data supported from the 56s therefore we have had that caution that might not be the same with mdma, for instance, or for that matter, maybe ketamine. So there are these cautions in autism. Interesting. But that could possibly also, at least theoretically, maybe be a bit destabilizing. I'm sure it would be brilliant and helpful for some. But if you go for some indications, another example could be emotional unstable personality, where again a bit the same thing with the sense of self. If you fragment that on top, it might be destabilizing. But I still think, and we have some data to support it from surveys where we have followed people out in the real world, that it might still be helpful overall as a group, but the likelihood of being really tricky and challenging seems higher. It looks higher. Therefore, if you were to do such work, proper trials, at least do it with the experts who are really good at providing the right support and care for that specific group of patients in order to do such trials safely and really monitor them and see how we are making it worse for some people. So I think there are some cautions in some directions, but the field will keep on moving and expanding and hopefully it will be colleagues who are really cautious about, I'm sure.

[Podcast Host]

Do you feel the myths have been busted or do people still have quite negative preconceptions when you tell them what you're studying?

[Dr. David Aborizo]

You know what? I think that actually the science is helpful for moving this forward. Also outside, way outside of science that as we understand more about how they work in the brain, when we see the trials that the safety data are convincing and the effects and the help that people feel and the improvements, that data that is being published is being covered by media, including right now here by you, that makes people shift a bit. And that does break the stigma down. That as so many other things. Although the ketamine story is a really complex story to tell, it's not that black and white. And when people get better understanding of the nuances and the pros and cons and where it might be beneficial and where. Where caution is really important, then these stigmas are being reduced. And that's always healthy to put more nuance onto the story. But that will also mean that people recreation will be using it. We are seeing that more psychedelics.

[Podcast Host]

And just finally, if somebody has a severe addiction and this is the way that they are led to hopefully cure or treat that addiction. Because addicts tend to say they're addicts for the rest of their lives, don't they, in terms of how they deal with it. How quickly do you see people turning their lives around? What's the kind of.

[Dr. David Aborizo]

For addiction specifically? We are doing these new trials with gambling use disorder. Gambling disorder and opiate use disorder at Imperial with therapy. So we haven't actually ourselves done a full addiction study, but the colleagues who have. What you see in those trials is with like same as in all other psychedelic studies. You have that profound experience. We can even see that meshes of how profound that experience was and how rich and maybe spiritual, mystical it is. The better clinical outcomes across a lot of these trials, which is fascinating and really speaking to a very different paradigm to what we're used to. But the effects come. They are immediate. They are immediate effects like ketamine also has been a revolution in depression treatment because you have the antidepressant effect immediately, whereas with SSRIs typically a lap time of weeks. So these are very immediate effects. It's more about trying to prolong the effects by integrating and implementing and find out how this opportunity for change and that flexibility, how that can be used far after the experience on the drug. So the effects are.

[Podcast Host]

So I'm getting from you. It's not a magic bullet, but it does take work still. Like a lot of therapy takes work and it does take work for the individual who's going through it.

[Dr. David Aborizo]

A bit like physiotherapy.

[Podcast Host]

Yeah, yeah.

[Dr. David Aborizo]

It's a bit similar. Your sports.

[Podcast Host]

Yeah. Well, somebody can come and do physio on you, but you still have to do your own rehab and rehab afterwards or.

[Dr. David Aborizo]

And what is beautiful about it. And I think that's as I see this shift in psychiatry. If we just now focus on the treatment for mental illness that is a bit like. It's interventional, like phisher therapy. Right. It's something. It's an intense period and there's a lot of work to be done by the individual agency on the individual and work after. But you are really, you can get better. You can get better. It's an effort but. And it's an intense period. It's not that you're parked on a drug. Not that I speak down SSRIs or other mental health psychiatrists, we do prescribe them. Absolutely. But there's something appealing and beautiful about coming with more like an intervention and see if you can make things much better for people without needing to be on a medication forever. So more interventional psychiatry. I think that's where we are moving also with neurostimulation. Completely different field. We are working together and doing trials that incorporate both. And that's a bit same thinking it's interventional rather than just being on a maintenance treatment forever that sometimes doesn't even really help you that much to be a bit critical towards some of what we are doing day to day in psychiatry.

[Podcast Host]

Dr. David Aborizo, thank you so much. That was absolutely fascinating.

[Dr. David Aborizo]

Thanks so much for having me.

[Podcast Host]

Pleasure. Well, I hope you found that as interesting as I did. I know there's a lot to take in there, but if you're like me, it was an area that I think I really needed educating on. So hopefully you've taken something away from David's incredible knowledge. Do join us next time on the MIDPOINT.

[Fin AI Advertiser]

Foreign. Customer service. It's real and it works. And with fin, we've built the number one AI agent for customer service. We're seeing lots of cases where it's solving up to 90% of real queries for real businesses. This includes the real world, complex stuff like issuing a refund or canceling an order. And we also see it when FIN goes up against competitors. It's top of all the performance benchmarks, top of the G2 leaderboard. And if you're not happy, we'll refund you up to a million dollars, which I think says it all. Check it out for yourself. At fin, AI insurance isn't one size fits all. That's why drivers have enjoyed Progressive's Name your price tool for years. Now, with the Name your price tool, you tell them what you want to pay and they'll show you options that fit your budget. So whether you're picking out your first policy or just looking for something that works better for you and your family, they make it easy to see your options. Visit progressive.com find a rate that works for you with the name your price tool. Progressive Casualty Insurance Company and affiliates Price and Coverage Match limited by state law.